IN2014MN01622A - - Google Patents

Info

Publication number
IN2014MN01622A
IN2014MN01622A IN1622MUN2014A IN2014MN01622A IN 2014MN01622 A IN2014MN01622 A IN 2014MN01622A IN 1622MUN2014 A IN1622MUN2014 A IN 1622MUN2014A IN 2014MN01622 A IN2014MN01622 A IN 2014MN01622A
Authority
IN
India
Prior art keywords
present
aminopyrazine derivatives
malaria
medicament
inhibition
Prior art date
Application number
Other languages
English (en)
Inventor
Yassir Younis
Kelly Chibale
Michael John Witty
David Waterson
Original Assignee
Univ Cape Town
Medicines For Malaria Venture Mmv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cape Town, Medicines For Malaria Venture Mmv filed Critical Univ Cape Town
Publication of IN2014MN01622A publication Critical patent/IN2014MN01622A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IN1622MUN2014 2012-02-17 2013-02-15 IN2014MN01622A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600324P 2012-02-17 2012-02-17
PCT/IB2013/051235 WO2013121387A1 (en) 2012-02-17 2013-02-15 Anti -malarial agents

Publications (1)

Publication Number Publication Date
IN2014MN01622A true IN2014MN01622A (zh) 2015-05-15

Family

ID=48014134

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1622MUN2014 IN2014MN01622A (zh) 2012-02-17 2013-02-15

Country Status (21)

Country Link
US (1) US9266842B2 (zh)
EP (1) EP2814820B1 (zh)
JP (1) JP6226889B2 (zh)
CN (1) CN104136426B (zh)
BR (1) BR112014020212B1 (zh)
CA (1) CA2864483A1 (zh)
CY (1) CY1118074T1 (zh)
DK (1) DK2814820T3 (zh)
ES (1) ES2589283T3 (zh)
HK (1) HK1202859A1 (zh)
HR (1) HRP20161237T1 (zh)
HU (1) HUE029876T2 (zh)
IN (1) IN2014MN01622A (zh)
LT (1) LT2814820T (zh)
ME (1) ME02535B (zh)
PL (1) PL2814820T3 (zh)
PT (1) PT2814820T (zh)
SI (1) SI2814820T1 (zh)
SM (1) SMT201600441B (zh)
WO (1) WO2013121387A1 (zh)
ZA (1) ZA201406786B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2814820T (pt) * 2012-02-17 2016-10-25 Medicines For Malaria Venture Mmv Novos agentes antimaláricos
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017067881A1 (en) 2015-10-19 2017-04-27 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds for use in the treatment of parasitic protozoal infections
WO2019145360A1 (en) * 2018-01-24 2019-08-01 Glaxosmithkline Intellectual Property Development Limited Novel compounds for the treatment of parasitic infections
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途
WO2023094305A1 (en) * 2021-11-23 2023-06-01 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds useful in the treatment of parasitic protozoal infection
WO2024033281A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furo pyrimidine derivates
WO2024033280A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528302T3 (es) * 2003-12-03 2015-02-06 Ym Biosciences Australia Pty Ltd Heterociclos con 6 anillos de nitrógeno fenilsustituidos como inhibidores de la polimerización de microtúbulos
CN101472912A (zh) * 2006-06-22 2009-07-01 比奥维特罗姆上市公司 作为mnk激酶抑制剂的吡啶和吡嗪衍生物
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
HUE027946T2 (en) 2010-01-18 2016-11-28 Medicines For Malaria Venture Mmv New anti-malaria drugs
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
CA2828578A1 (en) * 2011-03-04 2012-09-13 Lexicon Pharmaceuticals, Inc. Mst1 kinase inhibitors and methods of their use
PT2814820T (pt) * 2012-02-17 2016-10-25 Medicines For Malaria Venture Mmv Novos agentes antimaláricos

Also Published As

Publication number Publication date
ES2589283T3 (es) 2016-11-11
BR112014020212B1 (pt) 2021-11-23
ZA201406786B (en) 2015-06-24
CN104136426B (zh) 2017-10-03
PL2814820T3 (pl) 2017-01-31
EP2814820A1 (en) 2014-12-24
HRP20161237T1 (hr) 2016-11-04
CN104136426A (zh) 2014-11-05
WO2013121387A1 (en) 2013-08-22
US9266842B2 (en) 2016-02-23
DK2814820T3 (en) 2016-10-03
JP2015507004A (ja) 2015-03-05
HK1202859A1 (zh) 2015-10-09
PT2814820T (pt) 2016-10-25
JP6226889B2 (ja) 2017-11-08
HUE029876T2 (en) 2017-04-28
LT2814820T (lt) 2016-10-25
US20150031682A1 (en) 2015-01-29
CA2864483A1 (en) 2013-08-22
BR112014020212A8 (pt) 2018-01-23
EP2814820B1 (en) 2016-07-20
SI2814820T1 (sl) 2016-10-28
CY1118074T1 (el) 2017-06-28
ME02535B (me) 2017-02-20
SMT201600441B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
IN2014MN01622A (zh)
WO2011086531A3 (en) New anti-malarial agents
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
IN2014MN02049A (zh)
IN2014MN00948A (zh)
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
IN2014MN01754A (zh)
IN2014MN00988A (zh)
EA023222B8 (ru) Пиразолилхиноксалиновые ингибиторы киназы
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014MN02069A (zh)
IN2014MN00986A (zh)
IN2014MN00987A (zh)
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
IN2014DN10670A (zh)
IN2015DN03854A (zh)
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
IN2015DN03998A (zh)
MX362879B (es) Usos novedosos.
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
IN2014DN10449A (zh)
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
HK1203149A1 (zh) 阿貝特羅的新劑型和製劑